Literature DB >> 32022822

Echocardiographic abnormalities in children and adolescents living with human immunodeficiency virus on highly active antiretroviral treatment.

Tewolde Wubayehu1, Workeabeba Abebe2, Endale Tefera3.   

Abstract

BACKGROUND: The availability and use of highly active antiretroviral treatment (HAART) has turned human immunodeficiency virus (HIV) into a chronic disease, allowing patients to live much longer.
OBJECTIVES: To report asymptomatic cardiac abnormalities in children and adolescents based on both conventional and tissue Doppler imaging (TDI) echocardiography.
METHODS: One hundred and fifty-one patients on HAART were recruited. Demographic and clinical variables were collected through patient interviews and medical record reviews. Conventional echocardiography and TDI were performed on each patient.
RESULTS: Mean age was 13.0 ± 3.2 (4.0-19.0) years. Eightythree patients (55%) were female. Age at diagnosis of HIV infection was 5.7 ± 3.3 years. Age at initiation of HAART was 7.34 ± 3.54 years, while duration of HAART was 59 ± 39.1 months. On conventional echocardiography, three cases of left ventricular (LV) systolic dysfunction, two of pulmonary hypertension and one of minimal pericardial effusion were identified. Calculation of myocardial mass index (MMI) revealed that 16 patients had abnormal values. Twenty-seven (17.9%) patients had evidence of LV diastolic dysfunction and 18 (11.9%) had right ventricular (RV) diastolic dysfunction. Nineteen (12.6%) patients had tricuspid annular systolic velocity of < 9.5 cm/s, indicating asymptomatic RV systolic dysfunction.
CONCLUSIONS: While few patients had abnormalities such as reduced LV ejection fraction, pulmonary hypertension and minimal pericardial effusion detectable on conventional echocardiography, a larger proportion of patients had subtle abnormalities such as increased MMI, LV diastolic dysfunction on TDI, RV dysfunction and abnormal myocardial performance index. Such patients may need routine screening and cardiac follow up.

Entities:  

Keywords:  HIV‐infected children; cardiac involvement; myocardial mass index; tissue Doppler imaging; echocardiographic abnormalities

Mesh:

Year:  2020        PMID: 32022822      PMCID: PMC8762800          DOI: 10.5830/CVJA-2019-072

Source DB:  PubMed          Journal:  Cardiovasc J Afr        ISSN: 1015-9657            Impact factor:   1.167


  31 in total

1.  Usefulness of the myocardial performance index for early detection of anthracycline-induced cardiotoxicity in children.

Authors:  B W Eidem; B G Sapp; C R Suarez; F Cetta
Journal:  Am J Cardiol       Date:  2001-05-01       Impact factor: 2.778

Review 2.  Myocardial performance index (Tei index): evaluating its application to myocardial infarction.

Authors:  Emmanouil N Karatzis; Anna T Giannakopoulou; John E Papadakis; Athanassios V Karazachos; Nearchos S Nearchou
Journal:  Hellenic J Cardiol       Date:  2009 Jan-Feb

3.  Left ventricular structure and function in children infected with human immunodeficiency virus: the prospective P2C2 HIV Multicenter Study. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group.

Authors:  S E Lipshultz; K A Easley; E J Orav; S Kaplan; T J Starc; J T Bricker; W W Lai; D S Moodie; K McIntosh; M D Schluchter; S D Colan
Journal:  Circulation       Date:  1998-04-07       Impact factor: 29.690

4.  Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement.

Authors:  A Pugliese; D Isnardi; A Saini; T Scarabelli; R Raddino; D Torre
Journal:  J Infect       Date:  2000-05       Impact factor: 6.072

5.  Cardiac complications in children with human immunodeficiency virus infection. Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection (P2C2 HIV) Study Group, National Heart, Lung, and Blood Institute.

Authors:  T J Starc; S E Lipshultz; S Kaplan; K A Easley; J T Bricker; S D Colan; W W Lai; W M Gersony; G Sopko; D S Moodie; M D Schluchter
Journal:  Pediatrics       Date:  1999-08       Impact factor: 7.124

6.  Doppler tissue imaging unmasks right ventricular function abnormalities in HIV-infected patients.

Authors:  Apostolos Karavidas; Dimitris Tsiachris; George Lazaros; George Xylomenos; Sophia Arapi; Nikolaos Potamitis; Vassiliki Matzaraki; John Caplanis; Evangelos Matsakas; Panos Gargalianos; Vlassis Pyrgakis; Christodoulos Stefanadis
Journal:  Cardiol J       Date:  2010       Impact factor: 2.737

7.  Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT).

Authors:  Nazzareno Galiè; Marius M Hoeper; Marc Humbert; Adam Torbicki; Jean-Luc Vachiery; Joan Albert Barbera; Maurice Beghetti; Paul Corris; Sean Gaine; J Simon Gibbs; Miguel Angel Gomez-Sanchez; Guillaume Jondeau; Walter Klepetko; Christian Opitz; Andrew Peacock; Lewis Rubin; Michael Zellweger; Gerald Simonneau
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

8.  Cardiac status of children infected with human immunodeficiency virus who are receiving long-term combination antiretroviral therapy: results from the Adolescent Master Protocol of the Multicenter Pediatric HIV/AIDS Cohort Study.

Authors:  Steven E Lipshultz; Paige L Williams; James D Wilkinson; Erin C Leister; Russell B Van Dyke; William T Shearer; Kenneth C Rich; Rohan Hazra; Jonathan R Kaltman; Denise L Jacobson; Laurie B Dooley; Gwendolyn B Scott; Nicole Rabideau; Steven D Colan
Journal:  JAMA Pediatr       Date:  2013-06       Impact factor: 16.193

9.  Cardiac manifestations in HIV-infected Thai children.

Authors:  Yupada Pongprot; Rekwan Sittiwangkul; Suchaya Silvilairat; Virat Sirisanthana
Journal:  Ann Trop Paediatr       Date:  2004-06

Review 10.  Antiretroviral treatment, management challenges and outcomes in perinatally HIV-infected adolescents.

Authors:  Allison L Agwu; Lee Fairlie
Journal:  J Int AIDS Soc       Date:  2013-06-18       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.